StockData
BioNexus Gene Lab Corp logo

BioNexus Gene Lab Corp (BGLC) stock

BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3089% below fair value
$0.77−0.05 (-6.56%)

Close on Nov 17, 2026Market cap $2.25MP/E –Yield –

BioNexus Gene Lab ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

BioNexus Gene Lab's ebitda for the twelve months ending Dec 31, 2019 was -$233.99K, down 332.8% year over year. For fiscal 2019 it was -$233.99K, down 332.8% from the year before.

Annual ebitda

PeriodPeriod endValueChange
FY2019Dec 31, 2019-$233.99K-332.8%
FY2018Dec 31, 2018$100.51K–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2019Dec 31, 2019-$85.73K–
Q3 FY2019Sep 30, 2019-$39.80K–
Q4 FY2018Dec 31, 2018-$53.51K–
Q3 FY2018Sep 30, 2018-$45.17K–

More BioNexus Gene Lab figures

See a number that looks wrong?